661 related articles for article (PubMed ID: 22288667)
1. Optimizing levodopa therapy to treat wearing-off symptoms in Parkinson's disease: focus on levodopa/carbidopa/entacapone.
Reichmann H; Emre M
Expert Rev Neurother; 2012 Feb; 12(2):119-31. PubMed ID: 22288667
[TBL] [Abstract][Full Text] [Related]
2. Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone.
Fung VS; Herawati L; Wan Y; ;
Mov Disord; 2009 Jan; 24(1):25-31. PubMed ID: 18846551
[TBL] [Abstract][Full Text] [Related]
3. [Optimization of use of levodopa in Parkinson's disease: role of levodopa-carbidopa-entacapone combination].
Castro A; Valldeoriola F; Linazasoro G; Rodriguez-Oroz MC; Stochi F; Marin C; Rodriguez M; Vaamonde J; Jenner P; Alvarez L; Pavon N; Macias R; Luquin MR; Hernandez B; Grandas F; Gimenez-Roldan S; Tolosa E; Obeso JA
Neurologia; 2005 May; 20(4):180-8. PubMed ID: 15891947
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic considerations for the use of levodopa in the treatment of Parkinson disease: focus on levodopa/carbidopa/entacapone for treatment of levodopa-associated motor complications.
Müller T
Clin Neuropharmacol; 2013; 36(3):84-91. PubMed ID: 23673910
[TBL] [Abstract][Full Text] [Related]
5. Immediate versus delayed switch from levodopa/carbidopa to levodopa/carbidopa/entacapone: effects on motor function and quality of life in patients with Parkinson's disease with end-of-dose wearing off.
Lew MF; Somogyi M; McCague K; Welsh M;
Int J Neurosci; 2011 Nov; 121(11):605-13. PubMed ID: 21843110
[TBL] [Abstract][Full Text] [Related]
6. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study.
Stocchi F; Rascol O; Kieburtz K; Poewe W; Jankovic J; Tolosa E; Barone P; Lang AE; Olanow CW
Ann Neurol; 2010 Jul; 68(1):18-27. PubMed ID: 20582993
[TBL] [Abstract][Full Text] [Related]
7. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340
[TBL] [Abstract][Full Text] [Related]
8. Direct switch from levodopa/benserazide or levodopa/carbidopa to levodopa/carbidopa/entacapone in Parkinson's disease patients with wearing-off: efficacy, safety and feasibility--an open-label, 6-week study.
Eggert K; Skogar O; Amar K; Luotonen L; Kuoppamäki M; Leinonen M; Nissinen H; Oertel W
J Neural Transm (Vienna); 2010 Mar; 117(3):333-42. PubMed ID: 20013007
[TBL] [Abstract][Full Text] [Related]
9. Levodopa/carbidopa/entacapone in Parkinson's disease.
Seeberger LC; Hauser RA
Expert Rev Neurother; 2009 Jul; 9(7):929-40. PubMed ID: 19589043
[TBL] [Abstract][Full Text] [Related]
10. Treatment of end-of-dose wearing-off in parkinson's disease: stalevo (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess/Comtan (entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment.
Brooks DJ; Agid Y; Eggert K; Widner H; Ostergaard K; Holopainen A;
Eur Neurol; 2005; 53(4):197-202. PubMed ID: 15970632
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson's disease patients with wearing-off.
Kuoppamäki M; Leinonen M; Poewe W
J Neural Transm (Vienna); 2015 Dec; 122(12):1709-14. PubMed ID: 26347184
[TBL] [Abstract][Full Text] [Related]
12. [Direct switch from conventional levodopa to stalevo (levodopa/carbidopa/entacapone) improves quality of life in Parkinson's disease: results of an open-label clinical study].
Litvinenko IV; Odinak MM; Mogil'naia VI; Sologub OS; Sakharovskaia AA
Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(1):51-4. PubMed ID: 19156087
[TBL] [Abstract][Full Text] [Related]
13. Role of the pharmacist in the effective management of wearing-off in Parkinson's disease.
Simonson W; Hauser RA; Schapira AH
Ann Pharmacother; 2007 Nov; 41(11):1842-9. PubMed ID: 17878397
[TBL] [Abstract][Full Text] [Related]
14. Comparison of 200 mg retarded release levodopa/carbidopa - with 150 mg levodopa/carbidopa/entacapone application: pharmacokinetics and efficacy in patients with Parkinson's disease.
Müller T; Ander L; Kolf K; Woitalla D; Muhlack S
J Neural Transm (Vienna); 2007; 114(11):1457-62. PubMed ID: 17564755
[TBL] [Abstract][Full Text] [Related]
15. Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease.
Hauser RA; Panisset M; Abbruzzese G; Mancione L; Dronamraju N; Kakarieka A;
Mov Disord; 2009 Mar; 24(4):541-50. PubMed ID: 19058133
[TBL] [Abstract][Full Text] [Related]
16. Adherence with levodopa/carbidopa/entacapone versus levodopa/carbidopa and entacapone as separate tablets in patients with Parkinson's disease.
Delea TE; Thomas SK; Hagiwara M; Mancione L
Curr Med Res Opin; 2010 Jul; 26(7):1543-52. PubMed ID: 20429819
[TBL] [Abstract][Full Text] [Related]
17. A single-blind cross over study investigating the efficacy of standard and controlled release levodopa in combination with entacapone in the treatment of end-of-dose effect in people with Parkinson's disease.
Iansek R; Danoudis M
Parkinsonism Relat Disord; 2011 Aug; 17(7):533-6. PubMed ID: 21576031
[TBL] [Abstract][Full Text] [Related]
18. Clinical experience with the novel levodopa formulation entacapone + levodopa + carbidopa (Stalevo).
Silver DE
Expert Rev Neurother; 2004 Jul; 4(4):589-99. PubMed ID: 15853578
[TBL] [Abstract][Full Text] [Related]
19. Combining entacapone with levodopa/DDCI improves clinical status and quality of life in Parkinson's Disease (PD) patients experiencing wearing-off, regardless of the dosing frequency: results of a large multicentre open-label study.
Onofrj M; Thomas A; Vingerhoets F; Martin W; Giménez-Roldán S; Azulay JP; Bernhard G; Schmidt W; Markabi S
J Neural Transm (Vienna); 2004 Aug; 111(8):1053-63. PubMed ID: 15254793
[TBL] [Abstract][Full Text] [Related]
20. Comparison of IPX066 with carbidopa-levodopa plus entacapone in advanced PD patients.
Stocchi F; Hsu A; Khanna S; Ellenbogen A; Mahler A; Liang G; Dillmann U; Rubens R; Kell S; Gupta S
Parkinsonism Relat Disord; 2014 Dec; 20(12):1335-40. PubMed ID: 25306200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]